Sinovac’s Eupolio Vaccine Gains Market Authorization in China

Sinovac Biotech’s Eupolio vaccine, which is a Sabin inactivated poliovirus vaccines (sIPV) developed by Intravacc and out licensed to Sinovac, has gained marketing authorization in China from the Chinese National Medical Products Administration (NMPA).

The approval, which was announced in a July 20, 2021 press release, is a positive result for the ongoing efforts to eradicate the globe of polio. Intravacc had originally developed the vaccine for the purpose of providing low- and middle-income countries with the opportunity to produce their own safe polio vaccine.

According to the company press release, many vaccination campaigns to eradicate polio were put on hold or delayed during the COVID-19 pandemic. So, the approval of the Eupolio vaccine in China will help to close the gap between the supply and demand of inactivated polio vaccines for infants.

“This is a great example project in which Intravacc’s innovation and knowledge have been the foundation of the development of an affordable vaccine that contributes to the reduction of infectious disease burden on a global level,” said Jan Groen, Intravacc’s CEO, in the press release. “We have recently launched a similar program for our Avacc 10 COVID-19 nasal spray vaccine, intending to make this vaccine available to the world.”

Source: Intravacc